EASO Makes Semaglutide and Tirzepatide First-Line Drugs
EASO updated its 'living' obesity algorithm in Nature Medicine, placing semaglutide and tirzepatide as first-line and adding a split liver fibrosis pathway.
May 25, 2026 · 3 min read
The European Association for the Study of Obesity (EASO) has formally positioned semaglutide and tirzepatide at the top of its pharmacological treatment algorithm for obesity. The updated "living framework," published simultaneously in Nature Medicine and presented at the European Congress on Obesity (ECO 2026), recommends the two drugs as first-line treatment for adults with obesity and for most obesity-related complications — representing the most authoritative European clinical guidance to date on GLP-1 drug selection.
What happened
EASO's living framework is a continuously updated guideline, designed to incorporate new clinical evidence as it emerges rather than requiring a full revision cycle every few years. The 2026 update is the first to recommend semaglutide and tirzepatide explicitly as first-line agents across most obesity treatment indications, reflecting the strength of data from the STEP and SURMOUNT trial programs.
The update also introduces a meaningful structural change in how liver disease is handled. The 2025 version of the algorithm treated liver disease as a single domain. The 2026 update splits it into two separate pathways:
- MASH resolution (metabolic dysfunction-associated steatohepatitis, formerly NASH): Both semaglutide and tirzepatide are positioned side by side as equivalent options.
- Liver fibrosis improvement: Semaglutide is the recommended agent, based on more mature clinical evidence — specifically from the ESSENCE Phase 3 trial. Tirzepatide's fibrosis data exist but are currently less mature, derived largely from secondary endpoints rather than primary fibrosis endpoints in dedicated trials.
For weight loss as the primary goal in people without relevant complications, the algorithm now clearly indicates that tirzepatide is preferred based on consistently larger weight reductions across the SURMOUNT program compared to semaglutide in the STEP program.
Why it matters
EASO guidelines carry significant weight in European prescribing practice and health technology assessments — the same way the American Diabetes Association's standards influence US prescribing. Formal first-line status for semaglutide and tirzepatide will make it easier for European clinicians to prescribe these drugs early, rather than reserving them for patients who have already failed other interventions.
The fibrosis distinction is clinically significant. Metabolic liver disease is an increasingly recognized obesity complication, and having a guideline-backed reason to prefer semaglutide specifically for fibrosis gives clinicians a decision framework for patients presenting with elevated liver enzymes, fibrosis markers, or biopsy-confirmed disease. Until the ESSENCE trial data, semaglutide's role in liver fibrosis was inferred; the 2026 EASO update reflects the stronger evidence now in hand.
For tirzepatide, being flagged as the preferred option for maximum weight loss — in writing, in a Nature Medicine publication — reinforces the clinical case for its use in patients whose primary driver is weight reduction. The indirect comparison across different trials has always favored tirzepatide; the EASO document codifies that judgment.
What to watch
The EASO framework is described as "living" — meaning further updates are expected as Phase 3 retatrutide data mature through the TRIUMPH program and as orforglipron (Foundayo) accumulates real-world weight loss data. A future revision could add retatrutide to the algorithm if TRIUMPH-1's 28.3% weight loss result is confirmed in the full program and if FDA/EMA approval follows. That would create a three-drug first-line landscape at different efficacy tiers.
The EASO guidance does not directly govern insurance reimbursement in individual EU countries, but it influences the assessments conducted by national health technology bodies (NICE in the UK, IQWiG in Germany, HAS in France) — which do govern coverage.
Sources
Sources